Deal Team
Should you want to know more about this transaction, you can contact one of the team members above
HighLife is a medtech company focused on Transcatheter Mitral Valve Replacement (TMVR) for treating mitral regurgitation.
HighLife develops a minimally invasive prosthetic mitral valve implanted on a beating heart through the femoral vein and artery while preserving the native valve structure and respecting the surrounding anatomy.
Recognized as being best-in-class, the valve can be delivered trans-septally via the femoral vein in a reversible manner. The trans-septal route is the preferred route for both interventionists and patients as it avoids any surgery.
One of the few trans-septal valves in clinical development, HighLife competes with large international medtech companies and its technology offers differentiating features, notably: ease of use, self-centering and broad-fitting.
HighLife needed to raise funds to finance a US feasibility study and pivotal CE-marking study until 2021.
HighLife SAS was established in 2010 and is headquartered in Paris, France, with offices in Irvine (California). It is focused on the development of a novel transcatheter replacement system for treating mitral regurgitation. The technology aims at a beating heart procedure reducing trauma to the patients.
Should you want to know more about this transaction, you can contact one of the team members above
Bryan, Garnier & Co acted as Sole Financial Advisor to HighLife. We conducted a broad, international private placement process targeting specialist and generalist funds across Europe, the US and China.
This €32m series B investment round was led by renowned American & European VC funds: USVP and Andera Partners, together with Sectoral Asset Management and Jose Calle Gordo, the company’s Chairman; Sofinnova, the major shareholder, significantly reinvested as well.
This transaction demonstrates our ability to support management teams throughout a demanding fundraising process and to access relevant investors that are today required to achieve larger size of fundraising.
In 2018 Bryan, Garnier & Co closed 19 transactions involving healthcare growth companies across Europe and the US. In particular we were advisors to Moderna for its pre-IPO round, bookrunners for the Medartis IPO on the SIX Swiss Stock Exchange, advised the sale of TxCell to Sangamo Therapeutics, led the follow-on offering of Celyad on NASDAQ and advised Montagu in its LBO on Maincare.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are as essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.